#ESMO26 | Impressive results with a next-generation bispecific ADC!

Prof. Dr. Ahmet Dirican· @dr_dirican · X·2026-10-23 23:48· 2 天前评分70

正文 · 原文

Phase III PANKU-Breast01: EGFR×HER3-targeting iza-bren improved median PFS in HR+/HER2− metastatic breast cancer (8.2 vs 4.0 months; HR 0.41).

However, grade ≥3 treatment-related AEs reached 85.3%.

Key questions: Do ESR1, PIK3CA, or PTEN alterations influence response? What is the impact of prior ADC exposure?

#ESMO26 #BreastCancer #ADC @myESMO @oncodaily @OncoAlert

149 浏览 · 1 赞 · 0 转发 · 0 回复

会议摘要

LBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上

PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)

https://esmocongress.esmo.org

来源：Prof. Dr. Ahmet Dirican · x.com